Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
Study Details
Study Description
Brief Summary
Randomized phase II trial to compare the efficacy and safety of standard chemotherapy plus quizartinib versus standard chemotherapy plus placebo in adult patients with newly diagnosed FLT3 wild-type Acute Myeloid Leukemia
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 2 |
Detailed Description
Multicenter, prospective, randomized, placebo-controlled, double-blinded phase II trial to assess the efficacy and safety of an oral quizartinib vs. placebo containing front-line chemotherapy-based schedule in FMS-like tyrosine kinase 3 internal tandem duplications (FLT3-ITD) wild-type Acute Myeloid Leukemia patients.
The trial will be conducted in two phases:
An open-label safety run-in phase: Cytarabine 200 mg/m2 (days 1-7), Idarubicin 12 mg/m2 (days 1-3) Quizartinib 60 mg/d x 14 days (30mg with strong Cytochrome P450 Family 3 Subfamily A (CYP3A) inhibitor) in a total of 9 patients, being observed during 1 cycle of induction to define the final dose for the randomized phase.
A randomized double-blinded phase 2:1 quizartinib (at the established dose) vs. placebo.
Experimental Arm: Cytarabine 200 mg/m2 (days 1-7), Idarubicin 12 mg/m2 (days 1-3) Quizartinib 60 mg/d x 14 days (30mg with strong CYP3A inhibitor) Standard Arm: Cytarabine 200 mg/m2 (days 1-7), Idarubicin 12 mg/m2 (days 1-3) Placebo 60 mg/d x 14 days (30mg with strong CYP3A inhibitor)
272 patients will be included in this phase.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Quizartinib Induction: Cytarabine continuous IV infusion 200 mg/m2 (days 1-7), Idarubicin IV infusion 12 mg/m2 (days 1-3), oral quizartinib (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days. Consolidation: Cytarabine IV infusion 1,5-3 g/m2 (days 1, 3, 5), oral quizartinib (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days. Maintenance: oral quizartinib 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days |
Drug: Quizartinib
Induction: oral quizartinib (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days.
Consolidation: oral quizartinib (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days.
Maintenance: oral quizartinib 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days.
Drug: Cytarabine
Induction: Cytarabine continuous IV infusion, 200 mg/m2 (days 1-7), up to 2 cycles of 35 days.
Consolidation: Cytarabine IV infusion, 1,5-3 g/m2 (days 1, 3, 5), up to 4 cycles of 35 days.
Drug: Idarubicin
Induction: Idarubicin IV infusion 12 mg/m2 (days 1-3), up to 2 cycles of 35 days.
|
Placebo Comparator: Placebo Induction: Cytarabine continuous IV infusion 200 mg/m2 (days 1-7), Idarubicin IV infusion 12 mg/m2 (days 1-3), oral placebo (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days. Consolidation: Cytarabine IV infusion 1,5-3 g/m2 (days 1, 3, 5), oral placebo (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days. Maintenance: oral placebo 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days. |
Drug: Placebo oral tablet
Induction: oral placebo (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days.
Consolidation: oral placebo (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days.
Maintenance: oral placebo 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days.
Drug: Cytarabine
Induction: Cytarabine continuous IV infusion, 200 mg/m2 (days 1-7), up to 2 cycles of 35 days.
Consolidation: Cytarabine IV infusion, 1,5-3 g/m2 (days 1, 3, 5), up to 4 cycles of 35 days.
Drug: Idarubicin
Induction: Idarubicin IV infusion 12 mg/m2 (days 1-3), up to 2 cycles of 35 days.
|
Outcome Measures
Primary Outcome Measures
- Event-free survival rate [Through study completion, an average of 5 years]
Time from randomization to the date of the occurrence of any of the following events: CR/CRi after 1 or 2 induction cycles, death in CR/CRi or relapse, whichever occurs the first
Secondary Outcome Measures
- Maximum dose tolerated (MDT) and recommended phase 2 dose (Safety run-in phase) [At the end of Cycle 1 of Induction and up to 59 days (Safety run-in phase)]
To determine the maximum dose tolerated (MDT) and the recommended phase 2 dose
- Composite Complete Remission (CR/CRi) with minimal residual disease (MRD) negativity [Through study completion, an average of 5 years]
The proportion of subjects with complete response or complete remission with incomplete blood count recovery with Minimal residual disease negative
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [Through study completion, an average of 5 years]
Adverse events between experimental quizartinib containing schedule and standard arm
- Disease-free survival [Through study completion, an average of 5 years]
To compare the time from the first documentation of remission to the documentation of disease recurrence or death.
- Overall survival [Through study completion, an average of 5 years]
The number of days from randomization until death from any cause
- Cumulative incidence of Relapse [Through study completion, an average of 5 years]
To compare the time from the date of first Complete Response until date of hematological or extramedullary relapse
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Written informed consent in accordance with national, local, and institutional guidelines. The patient must provide informed consent before the first screening procedure. The patient and the investigator must sign informed consent form.
-
Diagnosis of untreated AML (according to the World Health Organization (WHO) 2008/2016 definition)
-
Age ≥ 18 and ≤70 years old at the time of screening
-
Non-FLT3-ITD (allelic ratio <0.03) at diagnosis
-
Considered eligible to receive intensive chemotherapy as per investigator judgment
-
Eastern Cooperative Oncology Group (ECOG) 0-2
-
No contraindications for quizartinib
-
The subject is receiving standard "7+3" induction chemotherapy regimen as specified in the protocol
-
No severe organ function abnormalities
-
Not included in other first-line trials
-
Cardiac ejection fraction ≥ 45% assessed by echocardiography or multiple-gated acquisition (MUGA).
-
Female patients of child-bearing potential must have a negative serum pregnancy test at screening and agree to use reliable methods of contraception upon enrollment, during the treatment period and for 3 months following the last dose of investigational drug or cytarabine, whichever is later
-
Male patients must use a reliable method of contraception (if sexually active with a female of child-bearing potential) upon enrollment, during the treatment period, and for 3 months following the last dose of investigational drug or cytarabine, whichever is later
-
Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
Exclusion Criteria:
-
Patients with a genetic diagnosis of acute promyelocytic leukemia
-
Age <18 years or >70 years
-
ECOG performance status of 3 or 4
-
Prior treatment for AML, except for the following allowances:
- Leukapheresis d) Treatment for hyperleukocytosis with hydroxyurea
-
Blastic phase of bcr/abl chronic myeloid leukemia.
-
Presence of an associated active and/or uncontrolled malignancy:
- Patients with another neoplastic disease, for whom the Investigator has a clinical suspicion of active disease at the time of enrollment. Note: Patients with adequately treated early stage squamous cell carcinoma of the skin, basal cell carcinoma of the skin, or cervical intraepithelial neoplasia are eligible for this study. Hormonal or adjuvant therapies will be allowed for breast cancer or prostate cancer as long as they are on a stable dose for at least 2 weeks before the first dose.
-
Known active and not controlled hepatitis B or hepatitis C infection. In the event of a positive viral load, please consult with the Sponsor
-
Known human immunodeficiency virus (HIV) infection (HIV testing is not required as part of this study)
-
Presence of any severe psychiatric disease or physical condition that, according to the physician´s criteria, contraindicates the inclusion of the patient into the clinical trial
-
Serum creatinine ≥ 250 μmol/l (≥ 2.5 mg/dL) (unless it is attributable to AML activity)
-
Bilirubin, alkaline phosphatase, or Serum glutamic oxaloacetic transaminase (SGOT) > 3 times the normal upper limit (unless it is attributable to AML activity)
-
Uncontrolled or significant cardiovascular disease, including any of the following:
-
Symptomatic bradycardia of fewer than 50 beats per minute, unless the subject has a pacemaker;
-
QT Comparison of Fridericia's (QTcF) >450 msec at Screening. Note: QTcF will be derived from the mean of triplicate readings;
-
Diagnosis of or suspicion of long QT syndrome (including family history of long QT syndrome);
-
Systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥ 110 mmHg;
-
History of clinically relevant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes)
-
History of a second (Mobitz II) or third-degree heart block (subjects with pacemakers are eligible if they have no history of fainting or clinically relevant arrhythmias while using the pacemaker)
-
An ejection fraction <45%
-
History of uncontrolled angina pectoris or myocardial infarction within 6 months prior to Screening
-
History of New York Heart Association Class 3 or 4 heart failure
-
Right bundle branch and left anterior hemiblock (bifascicular block), complete left bundle branch block
-
History of hypersensitivity to any excipients in the quizartinib/placebo tablets
-
Females who are pregnant or breastfeeding
-
Any patients with known significant impairment in gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of quizartinib.
-
Active acute or chronic Graft-Versus-Host-Disease (GVHD) requiring prednisone >10 mg or equivalent corticosteroid daily.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Complejo Hospitalario Universitario de A Coruña | Santiago De Compostela | A Coruña | Spain | 15706 |
2 | Complejo Hospitalario Universitario de Santiago | Santiago De Compostela | A Coruña | Spain | 15706 |
3 | Hospital Universitari Germans Trias i Pujol | Badalona | Barcelona | Spain | 08916 |
4 | Hospital General Univesitario de Castellón | Castellón De La Plana | Castellón | Spain | 12004 |
5 | Complejo Hospitalario Universitario de Gran Canaria Dr. Negrín | Las Palmas De Gran Canaria | Las Palmas | Spain | 35020 |
6 | Hospital Universitario Quirón Salud Madrid | Pozuelo De Alarcón | Madrid | Spain | 28223 |
7 | Hospital General Universitario Santa Lucía | Cartagena | Murcia | Spain | 30200 |
8 | Complejo Hospitalario Universitario de Vigo | Vigo | Pontevedra | Spain | 36312 |
9 | Hospital Universitario de Canarias | La Laguna | Santa Cruz De Tenerife | Spain | 38320 |
10 | Hospital Universitario de Basurto | Bilbao | Vizcaya | Spain | 48013 |
11 | Hospital Universitario de Galdakao | Galdakao | Vizcaya | Spain | 48960 |
12 | Complejo Hospitalario de Albacete | Albacete | Spain | 02006 | |
13 | Hospital General Universitario de Alicante | Alicante | Spain | 03010 | |
14 | Complejo Hospitalario Torrecárdenas | Almería | Spain | 04004 | |
15 | Hospital Universitari Vall Hebron | Barcelona | Spain | 08035 | |
16 | Hospital Universitario de Burgos | Burgos | Spain | 09006 | |
17 | Hospital Puerta del Mar | Cadiz | Spain | ||
18 | Hospital San Pedro de Alcántara | Cáceres | Spain | 10003 | |
19 | Complejo Hospitalario Regional Reina Sofía | Córdoba | Spain | 14004 | |
20 | Hospital Juan Ramón Jiménez | Huelva | Spain | 21005 | |
21 | Complejo Hospitalario de Jaén | Jaén | Spain | 23007 | |
22 | Complejo Hospitalario Lucus Augusti | Lugo | Spain | 27003 | |
23 | Fundación Jiménez Díaz | Madrid | Spain | 28040 | |
24 | Hospital Universitario 12 de Octubre | Madrid | Spain | 28041 | |
25 | Hospital Clínico San Carlos | Madrid | Spain | ||
26 | Hospital La Paz | Madrid | Spain | ||
27 | Hospital Ramón y Cajal | Madrid | Spain | ||
28 | Hospital Virgen de la Arrixaca | Murcia | Spain | ||
29 | Hospital Regional Universitario Málaga | Málaga | Spain | 29010 | |
30 | Hospital Universitario Virgen de la Victoria | Málaga | Spain | 29010 | |
31 | Hospital Universitario Central de Asturias | Oviedo | Spain | 33006 | |
32 | Complejo Universitario de Navarra | Pamplona | Spain | 31008 | |
33 | Complejo Hospitalario de Pontevedra | Pontevedra | Spain | 36071 | |
34 | Hospital Universitario de Salamanca | Salamanca | Spain | 37007 | |
35 | Hospital Universitario Marques de Valdecilla | Santander | Spain | 39008 | |
36 | Complejo Hospitalario Regional Virgen del Rocío | Sevilla | Spain | 41013 | |
37 | Hospital Nuestra Señora del Prado | Talavera De La Reina | Spain | ||
38 | Complejo Hospitalario de Toledo | Toledo | Spain | 45004 | |
39 | Hospital Clínico Universitario Valencia | Valencia | Spain | 46010 | |
40 | Hospital Universitario Dr. Peset Aleixandre | Valencia | Spain | 46017 | |
41 | Hospital Universitari i Politecnic La Fe | Valencia | Spain | 46026 | |
42 | Hospital Clínico Universitario de Valladolid | Valladolid | Spain | 47003 | |
43 | Hospital Clínico Universitario Lozano Blesa | Zaragoza | Spain | 50009 | |
44 | Hospital Universitario Miguel Servet | Zaragoza | Spain | 50009 | |
45 | Hospital Txagorritxu | Vitoria | Álava | Spain | 01009 |
Sponsors and Collaborators
- PETHEMA Foundation
- Dynamic Science S.L.
- Daiichi Sankyo, Inc.
Investigators
- Principal Investigator: Pau Montesinos, Hospital Universitari i Politecnic La Fe
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- QUIWI